Back to Journals » Cancer Management and Research » Volume 12

RETRACTED ARTICLE: Knockdown of circRAD18 Mitigates Breast Cancer Progression through the Regulation of miR-613/HK2 Axis

Authors Zang H, Li Y, Zhang X, Huang G

Received 21 December 2019

Accepted for publication 29 April 2020

Published 19 May 2020 Volume 2020:12 Pages 3661—3672

DOI https://doi.org/10.2147/CMAR.S243300

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Lu-Zhe Sun



This paper has been retracted.

Zang H, Li Y, Zhang X, Huang G. Cancer Manag Res. 2020;12:3661–3672.

The Editor and Publisher of Cancer Management and Research wish to retract the published article. Concerns were raised following the authors request to replace graphs in Figure 7. The authors explained that calculation errors had been made during the analysis of the data and the resulting graphs were too similar. The authors provided some original data relating to Figure 7; however, it was not satisfactory and was not able to adequately verify the reported findings. The Editor requested to retract the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Creative Commons License © 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.